John M. Lambert. PhD

Consultant/Scientific Advisor
Former CSO and executive at ImmunoGen
Honorary Professor, Queen’s University Belfast, Northern Ireland, UK.

Dr. John Lambert has a longstanding and well recognized history working in the ADC field. In 1982, Dr. Lambert joined the Dana-Farber Cancer Institute, Harvard Medical School, working on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics, before joining ImmunoGen in 1987. After working in a variety of roles at the company, Dr. Lambert served as Chief Scientific Officer from 2008 until 2015. In 2016, he became a Distinguished Research Fellow at the company until his retirement at the end of 2017. He served on the Executive Committee of the company as Executive Vice President, Research, from 2008 until 2016, followed by a year (2017) on the Executive Committee in an Emeritus capacity until retirement. During Dr Lambert’s tenure in leadership roles at ImmunoGen, the company invented the ADC technology that resulted in the Genentech/Roche drug, Kadcyla®, as well as numerous other ADCs taken into clinical development. One of these is ImmunoGen’s promising drug candidate, mirvetuximab soravtansine, an ADC currently in a phase 3 trial for the treatment of platinum-resistant ovarian cancer. In 2018, he was appointed as an Honorary Professor of Queen’s University Belfast, Northern Ireland, UK.

Vincent de Groot, PhD, CLP

Dr. de Groot has a track record in creating and capturing value, as biotech entrepreneur, business development executive and transactor. His profile blends biotech entrepreneurship mentality with hands-on big pharma experience in licensing, acquisitions and venturing. Dr. de Groot founded and led the ADC company Syntarga from inception to exit (Trade Sale). Syntarga discovered and developed [vic-]trastuzumab duocarmazine (SYD985), an ADC drug candidate currently in Phase 3 clinical development.